Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Sponsor: Verve Therapeutics, Inc.
Summary
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
Official title: A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2024-10-30
Completion Date
2027-12
Last Updated
2025-11-28
Healthy Volunteers
No
Interventions
VERVE-201
Intravenous (IV) infusion
Locations (10)
Clinical Study Center
Adelaide, Australia
Clinical Study Center
Melbourne, Australia
Clinical Study Center
Chicoutimi, Canada
Clinical Study Center
Montreal, Canada
Clinical Study Center
Toronto, Canada
Clinical Study Center
Cape Town, South Africa
Clinical Study Center
Johannesburg, South Africa
Clinical Study Center
Liverpool, United Kingdom
Clinical Study Center
London, United Kingdom
Clinical Study Center
Manchester, United Kingdom